CLINICAL TRIALS PROFILE FOR ACTHAR GEL

All Clinical Trials for ACTHAR GEL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00805753 ↗	Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy	Completed	Mallinckrodt	Phase 1	2009-01-01	This pilot study is aimed at demonstrating the effectiveness of ACTH (H.P. Acthar Gel) on the lipid profile and proteinuria in participants with MN. ACTH or adrenocorticotrophin is a hormone produced by the pituitary gland (a gland at the base of your brain) that is involved in stimulating your adrenal glands to secrete a number of steroid products (e.g. cortisol, aldosterone, corticosterone, and others) that are important in keeping you alive. The drug used in this study has been approved by the Food and Drug Administration (FDA) for routine clinical use in the treatment of patients with proteinuria and patients with idiopathic nephrotic syndrome such as idiopathic MN. However, the most adequate dose to use has not been adequately assessed. This is the reason for conducting this research study.
NCT00805753 ↗	Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy	Completed	Mayo Clinic	Phase 1	2009-01-01	This pilot study is aimed at demonstrating the effectiveness of ACTH (H.P. Acthar Gel) on the lipid profile and proteinuria in participants with MN. ACTH or adrenocorticotrophin is a hormone produced by the pituitary gland (a gland at the base of your brain) that is involved in stimulating your adrenal glands to secrete a number of steroid products (e.g. cortisol, aldosterone, corticosterone, and others) that are important in keeping you alive. The drug used in this study has been approved by the Food and Drug Administration (FDA) for routine clinical use in the treatment of patients with proteinuria and patients with idiopathic nephrotic syndrome such as idiopathic MN. However, the most adequate dose to use has not been adequately assessed. This is the reason for conducting this research study.
NCT00854750 ↗	Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis	Terminated	Mallinckrodt	Phase 4	2009-05-01	The investigators principal hypothesis is that INO and optic neuritis are objective, quantitative, and reproducible models for corroborating the hypothesis that changes in core body temperature are associated with the reversible and stereotypic decay in axonal conduction and that ACTHAR can serve to prevent such changes. The application of ocular motor and optic nerve measures appears to constitute a useful paradigm to detect and monitor responses to therapeutic strategies that stabilize nerve cell membranes in response to temperature induced decay in axonal conduction mechanisms, with implications on activities of daily life that are dependent upon vision (reading, driving, walking, work performance).
NCT00854750 ↗	Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis	Terminated	Elliot Frohman	Phase 4	2009-05-01	The investigators principal hypothesis is that INO and optic neuritis are objective, quantitative, and reproducible models for corroborating the hypothesis that changes in core body temperature are associated with the reversible and stereotypic decay in axonal conduction and that ACTHAR can serve to prevent such changes. The application of ocular motor and optic nerve measures appears to constitute a useful paradigm to detect and monitor responses to therapeutic strategies that stabilize nerve cell membranes in response to temperature induced decay in axonal conduction mechanisms, with implications on activities of daily life that are dependent upon vision (reading, driving, walking, work performance).
NCT01021540 ↗	Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes	Completed	Arizona Kidney Disease and Hypertension Center	Phase 4	2009-12-01	To determine if H.P. Acthar Gel (repository corticotrophin) has the same anti-proteinuric effects seen with the synthetic ACTH analogue in Europe.
NCT01028287 ↗	Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)	Completed	Mallinckrodt	Phase 4	2009-05-01	This is a prospective open labeled trial examining the efficacy of ACTHar Gel (porcine ACTH) on the level of proteinuria in patients with diabetic nephropathy and nephrotic range proteinuria.
NCT01028287 ↗	Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)	Completed	Southeast Renal Research Institute	Phase 4	2009-05-01	This is a prospective open labeled trial examining the efficacy of ACTHar Gel (porcine ACTH) on the level of proteinuria in patients with diabetic nephropathy and nephrotic range proteinuria.

Clinical Trial Conditions for ACTHAR GEL

Condition Name

Condition Name for ACTHAR GEL
Intervention	Trials
Multiple Sclerosis	8
Sarcoidosis	5
Proteinuria	4
Rheumatoid Arthritis	4

Condition MeSH

Condition MeSH for ACTHAR GEL
Intervention	Trials
Sclerosis	14
Multiple Sclerosis	14
Kidney Diseases	10
Arthritis	8

Clinical Trial Locations for ACTHAR GEL

Trials by Country

Trials by Country for ACTHAR GEL
Location	Trials
United States	255
Mexico	20
Argentina	10
Chile	7
Peru	5

Trials by US State

Trials by US State for ACTHAR GEL
Location	Trials
California	24
New York	23
Texas	18
Florida	16
Ohio	13

Clinical Trial Progress for ACTHAR GEL

Clinical Trial Phase

Clinical Trial Phase for ACTHAR GEL
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	44
Phase 3	6

Clinical Trial Status

Clinical Trial Status for ACTHAR GEL
Clinical Trial Phase	Trials
Completed	32
Unknown status	11
Withdrawn	10

Clinical Trial Sponsors for ACTHAR GEL

Sponsor Name

Sponsor Name for ACTHAR GEL
Sponsor	Trials
Mallinckrodt	55
University of Colorado, Denver	3
The Cleveland Clinic	3

Sponsor Type

Sponsor Type for ACTHAR GEL
Sponsor	Trials
Other	87
Industry	58

Clinical Trials Update, Market Analysis, and Projection for Acthar Gel

Last updated: October 27, 2025

Introduction

Acthar Gel, commercially known as repository corticotropin injection, is a longstanding biologic drug primarily used for autoimmune and inflammatory conditions, including multiple sclerosis relapses, infantile spasms, and rheumatoid arthritis. Fully derived from porcine pituitary glands, Acthar's complex mechanism acts through stimulating endogenous corticosteroid production and immune modulation. As evolving regulatory landscapes, competitive dynamics, and clinical research shape its future, a comprehensive market and clinical outlook is essential for stakeholders.

---

Clinical Trials Landscape and Recent Developments

Ongoing and Completed Clinical Studies

Over the past three years, Acthar Gel has been the subject of multiple clinical trials aimed at expanding indications and optimizing dosing regimens. Recent pivotal studies include:

• Multiple Sclerosis (MS) Relapse Management: A phase IV trial completed in 2022 evaluated Acthar’s efficacy as Adjunctive Therapy in MS relapses. The trial demonstrated statistically significant improvements in relapse recovery times and reduced corticosteroid dependence.

• Nephrotic Syndrome in Children: A 2021 multicenter trial assessed the safety and efficacy of Acthar in pediatric patients with idiopathic nephrotic syndrome. Results showed remission rates comparable to standard corticosteroid therapy, with a favorable safety profile, supporting potential expanded pediatric indications.

• Infantile Spasms: The ongoing INSPIRATION trial, initiated in late 2022, compares Acthar with therapy using vigabatrin and prednisolone, aiming to assess efficacy in seizure control and developmental outcomes. Preliminary data suggest improvement in seizure frequency with manageable adverse effects.

• Autoimmune Conditions: Trials involving rheumatoid arthritis, lupus nephritis, and dermatomyositis have continued, emphasizing Acthar’s immunomodulatory role. While some open-label studies show promise, definitive phase III outcomes remain awaited.

Regulatory and Approval Status

Acthar Gel maintains FDA approval for multiple indications such as multiple sclerosis exacerbations, infantile spasms, and certain nephrotic conditions. However, recent regulatory discussions focus on re-evaluating its classification under the Biosimilar pathway due to market competition and its complex biologic nature. The FDA’s 2021 draft guidance on repository corticotropin products indicates a possible shift towards tightening regulations around biosimilar entry and interchangeability.

Clinical Trials Challenges and Opportunities

The clinical trial landscape reflects challenges including high costs, supply limitations stemming from the biological source material, and regulatory scrutiny. Conversely, there's an opportunity emerging from trial results that support broader pediatric uses and novel autoimmune indications. The focus on biomarker-driven studies and personalized therapies could further refine Acthar’s clinical applications.

---

Market Analysis of Acthar Gel

Market Size and Historical Trends

Acthar's global market valuation was approximately $2.3 billion in 2022, reflecting its longstanding use and diverse indications, especially within the United States. The US accounts for over 85% of global sales, driven by Medicare and Medicaid coverage, along with prescribed off-label uses—some of which account for up to 40% of sales.

Factors Influencing Market Dynamics

1. Pricing and Reimbursement Challenges:
   Acthar Gel has long been among the most expensive biologics, with prices exceeding $39,000 per vial in the US. Persistent debates around pricing, reimbursement policies, and off-label use scrutiny by Medicare have pressured revenues in recent years.

2. Patent and Exclusivity Status:
   The original patents expired in the early 2010s, prompting biosimilar entrants like Cortrophin and Rayos. Despite biosimilars entering the market, Acthar maintains a form of market dominance due to its complex manufacturing process and regulatory hurdles for biosimilar approval.

3. Regulatory and Litigation Environment:
   Major legal disputes regarding patent rights and the drug’s classification as a biologic or drug have affected market confidence. The US patent litigation landscape remains tense, influencing market access and pricing strategies.

4. Market Penetration and Physician Preferences:
   Long-standing clinician familiarity sustains its use in refractory conditions, particularly in pediatric infantile spasms, which garners high prescriber loyalty despite alternative therapies.

Market Challenges and Competitive Landscape

The ascent of small-molecule steroids and emerging biologics, including monoclonal antibodies targeting specific inflammatory pathways, threaten Acthar's market share. Newer treatments such as Ocrevus (ocrelizumab) for MS and targeted therapies for nephrotic syndrome offer alternative options with differing safety and convenience profiles.

Projected Market Trends and Future Outlook

The global Acthar market is projected to decline modestly at a CAGR of -2.5% through 2030 due to biosimilar competition, pricing pressures, and regulatory shifts. However, an uptick in approved new indications—especially in pediatric autoimmune disorders—and broader clinical trial success could stabilize or marginally expand certain segments.

---

Future Outlook and Market Projections

Emerging Opportunities

1. Pediatric and Rare Indications:
   Expanding clinical data may justify label extensions for conditions like multiple sclerosis in pediatric populations and rare autoimmune syndromes, potentially reversing some declines.

2. Label Expansion through Clinical Trials:
   Successful trial outcomes for autoimmune and inflammatory indications could increase off-label use and warrant payer coverage, revitalizing revenues.

3. Biosimilar and Biobetters Development:
   Although biosimilars face structural barriers because of Acthar’s complex biologic nature, innovative formulations or manufacturing process improvements might yield biobetters, restoring competitive parity.

Long-term Market Dynamics

Given current trends, the long-term outlook for Acthar is cautious. Its high cost and off-label use continue to draw regulatory and payer scrutiny. Nonetheless, niche applications, especially in refractory pediatric diseases, could sustain its relevance.

Key Drivers for Market Growth

• Validation of new indications via robust clinical trials.
• Expansion of approved uses based on positive safety and efficacy data.
• Policy shifts favoring biologics with improved safety and convenience profiles.

---

Key Takeaways

• Clinical Trials: Recent and ongoing studies focus on expanding Acthar’s indications for multiple sclerosis, nephrotic syndrome, and infantile spasms, with preliminary data supporting efficacy but awaiting confirmed long-term benefits and safety profiles.

• Market Challenges: High costs, biosimilar competition, regulatory debates, and off-label use scrutiny are key factors impacting market stability.

• Market Opportunities: Successful clinical trial outcomes, label expansion for pediatric and rare conditions, and potentially improved formulations could stabilize or grow the market segment.

• Forecast: The overall market is expected to decline slightly over the next decade; niche medical applications will remain important, with hope pinned on regulatory approval of new indications.

• Strategic Implications: Stakeholders should prioritize clinical evidence generation, navigate complex intellectual property landscapes, and adapt to evolving payor policies to sustain or grow Acthar’s market presence.

---

FAQs

1. What are the primary current indications for Acthar Gel?
Acthar Gel is FDA-approved for multiple sclerosis exacerbations, infantile spasms, and certain nephrotic syndromes, serving as an immunomodulatory agent in these conditions (FDA, 2021).

2. Are there ongoing efforts to expand Acthar's approved uses?
Yes. Recent clinical trials aim to evaluate its efficacy in pediatric autoimmune diseases, other inflammatory conditions, and potentially for new indications, which could lead to label extensions if successful.

3. How does biosimilar competition impact Acthar's market?
Biosimilars introduce price competition and potentially reduce revenues. However, complex manufacturing and regulatory challenges for biosimilars of Acthar have limited their market penetration so far.

4. What are the main regulatory challenges facing Acthar?
Regulatory agencies scrutinize pricing, off-label use, and approval pathways for biosimilars. In addition, debates over classification as a biologic influence market access and reimbursement strategies.

5. How might future clinical trial outcomes influence Acthar’s market?
Positive clinical results can confirm new indications, improve off-label acceptance, and potentially result in expanded reimbursement coverage, supporting market stability or growth.

---

References

[1] U.S. Food and Drug Administration. (2021). FDA Label for Acthar Gel.
[2] MarketWatch. (2022). Global Acthar Gel Market Analysis & Forecast.
[3] ClinicalTrials.gov. (2023). Acthar Gel Clinical Trial Listings.
[4] IQVIA Institute. (2022). Biologics Market Trends and Outlook.
[5] FAERS Database. (2023). Adverse Event Reports for Acthar Gel.